# Hepatitis E Diagnostic Test Market

> Hepatitis E Diagnostic Test Market Research Report: Size, Share, Trend Analysis By Test Type (Immunoassay-Based Tests, Molecular Diagnostics Tests, Serological Tests), By Sample Type (Serum, Plasma, Fecal), By End Users (Hospitals, Diagnostic Laboratories, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.57%
- **2024:** $ 2.05 Billion
- **2025:** $ 2.18 Billion
- **2035:** $ 4.12 Billion
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Siemens Healthineers (DE), Mylab Discovery Solutions (IN), Genetic Technologies Limited (AU), Wondfo Biotech (CN)

**Report ID:** MRFR/MED/27706-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/hepatitis-e-diagnostic-test-market-29424

---

## Market Summary

## **Hepatitis E Diagnostic Test Market Overview**

As per MRFR analysis, the Hepatitis E Diagnostic Test Market Size was estimated at 2.05 (USD Billion) in 2024. The Hepatitis E Diagnostic Test Market Industry is expected to grow from 2.18 (USD Billion) in 2025 to 3.87 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.57% during the forecast period (2025 - 2034).

### **Key Hepatitis E Diagnostic Test Market Trends Highlighted**

The global Hepatitis E diagnostic test market exhibits a growing demand due to the increasing prevalence of hepatitis E virus (HEV) infections worldwide.

Technological advancements in diagnostic techniques, such as the development of highly sensitive and specific molecular assays, have significantly contributed to the market growth.

Additionally, rising awareness about hepatitis E and the importance of early diagnosis drive the market expansion.

Key market drivers include the surge in hepatitis E outbreaks, particularly in developing countries with poor sanitation and hygiene practices. Opportunities for market expansion lie in the development of rapid and point-of-care diagnostic tests that can facilitate early detection and timely intervention in remote or resource-limited settings.

Recent trends in the market include the integration of artificial intelligence (AI) and machine learning (ML) algorithms into diagnostic platforms to enhance accuracy and efficiency. The market is also witnessing a shift toward non-invasive testing methods, such as saliva-based assays, for improved patient convenience and reduced discomfort.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Hepatitis E Diagnostic Test Market Drivers**

### Rising Prevalence of Hepatitis E Virus Infections

Hepatitis E is a viral infection that can cause inflammation of the liver. It is spread through contact with contaminated food or water, and it is a major public health concern in many developing countries. The World Health Organization (WHO) estimates that 20 million people are infected with hepatitis E each year, and that 3.4 million of these infections result in hospitalization.

The rising prevalence of hepatitis E virus infections is a major driver of the growth of the global Hepatitis E Diagnostic Test Market Industry.

As the number of people infected with hepatitis E increases, the demand for diagnostic tests to identify and treat the infection will also increase.

### Increasing Awareness of Hepatitis E

The increasing awareness of hepatitis E is another major driver of the growth of the global Hepatitis E Diagnostic Test Market Industry. In the past, hepatitis E was often misdiagnosed as other liver diseases, such as hepatitis A or B.

However, as awareness of hepatitis E has increased, so has the demand for diagnostic tests to identify the infection. This increased awareness is due in part to the efforts of public health organizations and advocacy groups, which have worked to raise awareness of the disease and its symptoms.

As a result of these efforts, more people are aware of hepatitis E and are seeking testing for the infection.

### Technological Advancements in Hepatitis E Diagnostics

The technological advancements in hepatitis E diagnostics are also driving the growth of the global Hepatitis E Diagnostic Test Market Industry. In the past, hepatitis E was diagnosed using serological tests, which detected antibodies to the virus.

However, these tests were not always accurate, and they could not be used to diagnose early-stage infections. In recent years, new diagnostic tests have been developed that are more accurate and sensitive than serological tests.

These new tests can be used to diagnose early-stage infections, and they can also be used to differentiate between hepatitis E and other liver diseases.

## **Hepatitis E Diagnostic Test Market Segment Insights**

### **Hepatitis E Diagnostic Test Market Test Type Insights**

The Global Hepatitis E Diagnostic Test Market is segmented by Test Type into Immunoassay-Based Tests, Molecular Diagnostics Tests, and Serological Tests. Among these segments, Immunoassay-Based Tests accounted for the largest market share in 2023, and is projected to continue its dominance throughout the forecast period.

The growth of this segment can be attributed to the increasing adoption of rapid diagnostic tests (RDTs), which are simple to use, provide quick results, and are cost-effective. The Molecular Diagnostics Tests segment is anticipated to be the fastest-growing segment in the Global Hepatitis E Diagnostic Test Market during the forecast period.

The growth of this segment can be attributed to the increasing demand for accurate and sensitive diagnostic tests for Hepatitis E virus (HEV). The Serological Tests segment is expected to witness steady growth over the forecast period, due to the continued use of traditional serological tests for the diagnosis of Hepatitis E.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Hepatitis E Diagnostic Test Market Sample Type Insights**

The Global Hepatitis E Diagnostic Test Market is segmented by Sample Type into Serum, Plasma, and Fecal. Among these, the Serum segment held the largest market share in 2023, accounting for over 45% of the global market revenue. This dominance is attributed to the widespread availability of serum samples and the ease of collection compared to other sample types.

The Plasma segment is expected to witness significant growth over the forecast period, owing to the increasing adoption of plasma-based diagnostic tests for Hepatitis E virus (HEV) detection.

The Fecal segment is projected to grow at a steady pace due to the growing awareness of fecal-oral transmission of HEV.

### **Hepatitis E Diagnostic Test Market End User Insights**

The end user segment of the Global Hepatitis E Diagnostic Test Market plays a crucial role in driving market growth. Hospitals account for a significant share of the market, owing to the increasing number of hepatitis E cases and the need for accurate and timely diagnosis.

Diagnostic laboratories are also major end users, as they provide specialized testing services for hepatitis E. Research institutes contribute to market growth by conducting research on new diagnostic methods and technologies. The growing focus on early detection and diagnosis of hepatitis E is expected to boost the demand for diagnostic tests, particularly in regions with high disease prevalence.

### **Hepatitis E Diagnostic Test Market Regional Insights**

The regional market for Hepatitis E Diagnostic Tests is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East Africa. In 2023, the North American market held the largest market share, followed by Europe and Asia-Pacific.

The growth in the North American market is primarily attributed to the increasing prevalence of hepatitis E, the growing adoption of advanced diagnostic technologies, and the presence of well-established healthcare infrastructure. The European market is expected to witness steady growth due to the rising awareness about hepatitis E and the availability of advanced healthcare facilities.

The Asia-Pacific market is anticipated to grow at a significant rate, owing to the increasing healthcare expenditure and the growing awareness about hepatitis E in the region. The South American and Middle East Africa markets are expected to grow at a slower pace due to the limited healthcare infrastructure and the lower prevalence of hepatitis E in these regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Hepatitis E Diagnostic Test Market Key Players and Competitive Insights**

Major players in the Hepatitis E Diagnostic Test Market are focusing on developing innovative diagnostic tests to improve the accuracy and efficiency of hepatitis E diagnosis. The industry is characterized by the presence of leading players such as Abbott Laboratories, Beckman Coulter, bioMérieux, Chembio Diagnostics, and F. Hoffmann-La Roche.

These companies are investing heavily in research and development to gain a competitive edge and meet the growing demand for accurate and reliable diagnostic tests.

The Hepatitis E Diagnostic Test Market is expected to witness significant development in the coming years, driven by factors such as the rising prevalence of hepatitis E infections, increasing awareness about the disease, and government initiatives to control the spread of the virus.

The competitive landscape is expected to remain dynamic, with new entrants and existing players vying for market share.

Among the leading Hepatitis E Diagnostic Test Market players, Abbott Laboratories is a global leader in the development and manufacturing of diagnostic tests and systems. The company offers a range of diagnostic tests for hepatitis E, including the ARCHITECT i2000SR and ARCHITECT i4000SR systems.

These systems provide automated and rapid testing, enabling healthcare professionals to diagnose hepatitis E infections quickly and accurately. Abbott Laboratories has a strong distribution network and a wide customer base, which contributes to its leading position in the market.

A notable competitor in the Hepatitis E Diagnostic Test Market is bioMérieux, a French multinational corporation specializing in in vitro diagnostics. The company offers a range of diagnostic tests for hepatitis E, including the VIDAS HEV IgM and VIDAS HEV IgG tests.

These tests are designed to detect antibodies against the hepatitis E virus, enabling healthcare professionals to diagnose acute and chronic hepatitis E infections. bioMérieux has a strong presence in Europe and Asia-Pacific and is expanding its operations in emerging markets, which is expected to drive its growth in the Hepatitis E Diagnostic Test Market.

### **Key Companies in the Hepatitis E Diagnostic Test Market Include**

## Hepatitis E Diagnostic Test Market Industry Developments

- **Q1 2024: Roche launches new Elecsys HEV IgM and IgG immunoassays for hepatitis E virus diagnosis** Roche announced the launch of its Elecsys HEV IgM and IgG immunoassays, expanding its diagnostic portfolio to include tests for hepatitis E virus, aimed at improving early detection and disease management.
- **Q2 2024: Altona Diagnostics releases RealStar HEV RT-PCR Kit 3.0 for hepatitis E virus detection** Altona Diagnostics introduced the RealStar HEV RT-PCR Kit 3.0, a CE-IVD marked molecular diagnostic test for the detection of hepatitis E virus RNA, targeting clinical laboratories in Europe.
- **Q2 2024: Dia.Pro launches new HEV ELISA kits for improved hepatitis E diagnosis** Dia.Pro Diagnostic Bioprobes announced the launch of new ELISA kits for hepatitis E virus, designed to enhance sensitivity and specificity in clinical diagnostics.
- **Q2 2024: Wantai receives regulatory approval for HEV IgM rapid test in Southeast Asia** Beijing Wantai Biological Pharmacy Enterprise obtained regulatory clearance for its HEV IgM rapid diagnostic test in several Southeast Asian countries, expanding access to point-of-care hepatitis E testing.
- **Q3 2024: Fortress Diagnostics launches new hepatitis E rapid test for global markets** Fortress Diagnostics announced the global launch of its hepatitis E rapid test, designed for use in resource-limited settings to facilitate timely diagnosis.
- **Q3 2024: MP Biomedicals expands hepatitis E diagnostic portfolio with new molecular assay** MP Biomedicals introduced a new molecular assay for hepatitis E virus detection, aiming to improve diagnostic accuracy in clinical laboratories.
- **Q4 2024: Primerdesign launches CE-marked hepatitis E virus RT-PCR kit** Primerdesign announced the launch of a CE-marked RT-PCR kit for hepatitis E virus, targeting European clinical diagnostic markets.
- **Q4 2024: Gold Standard Diagnostics introduces new hepatitis E ELISA test for clinical use** Gold Standard Diagnostics released a new ELISA test for hepatitis E virus, designed to support laboratories in accurate serological diagnosis.
- **Q1 2025: Mikrogen launches recomLine HEV IgG/IgM immunoblot for hepatitis E confirmation** Mikrogen GmbH announced the launch of its recomLine HEV IgG/IgM immunoblot, a confirmatory test for hepatitis E virus serology.
- **Q2 2025: AccuBioTech receives CE-IVD approval for new hepatitis E rapid test** AccuBioTech Co., Ltd. received CE-IVD approval for its hepatitis E rapid test, enabling distribution across European markets.
- **Q2 2025: Dia.Pro partners with European distributor for hepatitis E diagnostic kits** Dia.Pro Diagnostic Bioprobes announced a partnership with a major European distributor to expand the reach of its hepatitis E diagnostic kits.
- **Q3 2025: Altona Diagnostics signs supply agreement for RealStar HEV RT-PCR kits with national health authority** Altona Diagnostics entered into a supply agreement with a national health authority to provide RealStar HEV RT-PCR kits for hepatitis E virus surveillance and outbreak response.

## **Hepatitis E Diagnostic Test Market Segmentation Insights**

### **Hepatitis E Diagnostic Test Market Test Type Outlook**

### **Hepatitis E Diagnostic Test Market Sample Type Outlook**

### **Hepatitis E Diagnostic Test Market End User Outlook**

### **Hepatitis E Diagnostic Test Market Regional Outlook**

## Market Drivers

### Rising Incidence of Hepatitis E

The increasing incidence of Hepatitis E infections is a primary driver for the Hepatitis E Diagnostic Test Market. Reports indicate that Hepatitis E is becoming more prevalent, particularly in regions with inadequate sanitation and water quality. The World Health Organization has noted that Hepatitis E is endemic in many developing countries, leading to a heightened demand for effective diagnostic tests. As the number of reported cases rises, healthcare providers are compelled to seek reliable diagnostic solutions to manage and control outbreaks. This trend suggests that the market for Hepatitis E diagnostic tests is likely to expand, as healthcare systems prioritize the identification and treatment of this viral infection. Consequently, the rising incidence of Hepatitis E is expected to significantly influence the growth trajectory of the Hepatitis E Diagnostic Test Market.

### Government Initiatives and Funding

Government initiatives aimed at combating infectious diseases are significantly impacting the Hepatitis E Diagnostic Test Market. Many countries are implementing national health programs that focus on improving diagnostic capabilities for Hepatitis E. These initiatives often include funding for research and development of new diagnostic tests, as well as public health campaigns to raise awareness about the disease. For instance, increased budget allocations for infectious disease control have been observed in various nations, which directly supports the development and distribution of Hepatitis E diagnostic tests. Such government backing not only enhances the availability of testing but also encourages collaboration between public health entities and private sector companies. This synergy is likely to foster innovation and expand the Hepatitis E Diagnostic Test Market.

### Technological Innovations in Testing

Technological advancements in diagnostic testing are propelling the Hepatitis E Diagnostic Test Market forward. Innovations such as rapid testing kits, molecular diagnostics, and point-of-care testing are enhancing the accuracy and speed of Hepatitis E detection. These advancements not only improve patient outcomes but also facilitate timely public health responses to outbreaks. The introduction of more sophisticated testing methods, including serological and nucleic acid tests, has expanded the diagnostic capabilities available to healthcare providers. As a result, the market is witnessing an influx of new products that cater to diverse healthcare settings. The integration of technology in diagnostics is likely to attract investment and research, further stimulating growth in the Hepatitis E Diagnostic Test Market.

### Increased Global Travel and Migration

Increased The Hepatitis E Diagnostic Test Industry. As people move across borders, the risk of spreading infectious diseases, including Hepatitis E, escalates. Travelers and migrants may encounter regions where Hepatitis E is endemic, leading to a higher likelihood of infection. This dynamic creates a pressing need for effective diagnostic tests to identify and manage cases promptly. Healthcare providers are increasingly recognizing the importance of screening travelers for Hepatitis E, particularly those returning from high-risk areas. The rise in international travel and migration patterns is likely to drive demand for Hepatitis E diagnostic tests, as public health authorities aim to mitigate the risks associated with cross-border disease transmission. Thus, the impact of increased The Hepatitis E Diagnostic Test Industry is expected to be substantial.

### Growing Demand for Preventive Healthcare

The growing emphasis on preventive healthcare is driving the Hepatitis E Diagnostic Test Market. As healthcare systems worldwide shift towards preventive measures, the importance of early detection and diagnosis of infectious diseases like Hepatitis E is becoming increasingly recognized. This trend is reflected in the rising demand for diagnostic tests that can identify infections before they lead to severe health complications. Preventive healthcare initiatives often include routine screening programs, which are likely to incorporate Hepatitis E testing, especially in high-risk populations. The proactive approach to health management is expected to create a robust market for Hepatitis E diagnostic tests, as healthcare providers seek to implement comprehensive screening strategies. Consequently, the focus on preventive healthcare is anticipated to significantly contribute to the growth of the Hepatitis E Diagnostic Test Market.

## Future Outlook

The Hepatitis E Diagnostic Test Market is projected to grow at a 6.57% CAGR from 2025 to 2035, driven by increasing awareness, technological advancements, and rising healthcare expenditures.

**New opportunities:**

- Development of rapid point-of-care testing kits
- Integration of AI for predictive diagnostics
- Expansion into emerging markets with tailored solutions

By 2035, the market is expected to achieve substantial growth, reflecting enhanced diagnostic capabilities and broader accessibility.

## Segment Insights

### By Test Type: Immunoassay-Based Tests (Largest) vs. Molecular Diagnostics Tests (Fastest-Growing)

In the Hepatitis E Diagnostic Test Market, the segment of Immunoassay-Based Tests holds the largest market share, reflecting their widespread usage due to their rapid results and cost-effectiveness. These tests are commonly employed in clinical settings, enabling healthcare providers to diagnose Hepatitis E quickly and efficiently, thereby making them the preferred choice among healthcare professionals. In contrast, Molecular Diagnostics Tests are gaining traction, contributing significantly to the overall market as they offer enhanced sensitivity and specificity. This shift towards molecular techniques indicates a rising demand for precise diagnostic capabilities amidst increasing awareness and prevalence of Hepatitis E.

Test Types: Immunoassay-Based Tests (Dominant) vs. Molecular Diagnostics Tests (Emerging)

Immunoassay-Based Tests stand out as the dominant force within the Hepatitis E Diagnostic Test Market, thanks to their ease of use and widespread familiarity among healthcare providers. These tests typically utilize enzyme-linked immunosorbent assays (ELISAs) to detect antibodies and antigens, making them instrumental in initiating timely treatment. On the other hand, Molecular Diagnostics Tests are emerging as a significant contender, leveraging advanced technologies such as Polymerase Chain Reaction (PCR) to provide not only rapid results but also enhanced accuracy in identifying Hepatitis E. Their ability to detect viral RNA in patients is driving their adoption, particularly in specialized diagnostics laboratories and research settings.

### By Sample Type: Serum (Largest) vs. Fecal (Fastest-Growing)

The Hepatitis E Diagnostic Test Market demonstrates a diverse distribution of market share across various sample types including serum, plasma, and fecal samples. Serum remains the largest contributor to the market, primarily due to its established utilization in diagnostic methodologies. In contrast, while plasma samples hold a significant position, fecal samples have begun to carve out a notable niche, gaining traction in recent studies highlighting their diagnostic potentials.

Sample Type: Serum (Dominant) vs. Fecal (Emerging)

Serum samples, being the dominant force in the Hepatitis E diagnostic landscape, benefit from their long-standing use in viral diagnostics, offering reliable results and broad applicability. The credibility of serum tests and their integration into standard testing protocols contribute to their continued prevalence. On the other hand, fecal samples are emerging as a promising alternative due to their non-invasive nature and the potential for early detection of Hepatitis E. This shift towards fecal diagnostics is fueled by advances in molecular techniques and heightened awareness of gastrointestinal manifestations of the infection, positioning fecal samples as an important future player in the market.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Hepatitis E Diagnostic Test Market, hospitals represent the largest end user segment, accounting for a significant share of the overall market. Hospitals are crucial as they serve as primary care facilities capable of diagnosing and treating Hepatitis E patients. On the other hand, diagnostic laboratories are swiftly gaining ground and emerging as a fast-growing segment due to the increased demand for testing services driven by rising awareness and prevalence of the disease.

End User: Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals play a dominant role in the Hepatitis E Diagnostic Test Market, being the primary point of healthcare access where initial screenings and treatments occur. Their extensive infrastructure, including specialized departments and skilled personnel, allows them to provide comprehensive diagnostic services. In contrast, diagnostic laboratories are emerging as a vital segment, fueled by advancements in testing technologies and a growing public focus on infectious disease management. These laboratories offer specialized testing services that are often faster and more efficient than traditional methods, catering to the rising demand for timely diagnosis. As healthcare strategies evolve, the synergy between hospitals and diagnostic labs will likely shape the future landscape of Hepatitis E testing.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for Hepatitis E diagnostic tests, holding approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing awareness of Hepatitis E, and supportive regulatory frameworks. The demand for rapid and accurate diagnostic tests is further fueled by rising incidences of Hepatitis E, particularly in vulnerable populations. The United States and Canada are the leading countries in this market, with major players like Abbott Laboratories and Roche Diagnostics dominating the landscape. The competitive environment is characterized by continuous innovation and partnerships among key players to enhance diagnostic capabilities. The presence of established healthcare systems and funding for research and development also contribute to the region's strong market position.

### Europe : Regulatory Support and Growth

Europe is the second-largest market for Hepatitis E diagnostic tests, accounting for approximately 30% of the global market share. The region benefits from stringent regulatory standards and a growing emphasis on infectious disease control. Increased funding for public health initiatives and research into Hepatitis E diagnostics are key growth drivers. Countries are also focusing on improving healthcare access, which is expected to boost demand for diagnostic tests. Germany, France, and the UK are leading countries in this market, with significant contributions from companies like Siemens Healthineers and Bio-Rad Laboratories. The competitive landscape is marked by collaborations between public health organizations and private sector players to enhance diagnostic technologies. The presence of innovative startups also adds to the dynamic nature of the market.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is witnessing rapid growth in the Hepatitis E diagnostic test market, holding about 20% of the global market share. The region's growth is driven by rising incidences of Hepatitis E, particularly in developing countries, and increasing healthcare investments. Government initiatives aimed at improving healthcare infrastructure and disease awareness are also significant catalysts for market expansion. China and India are the leading countries in this region, with a growing presence of companies like Wondfo Biotech and Mylab Discovery Solutions. The competitive landscape is evolving, with local manufacturers increasingly entering the market to meet the rising demand for affordable diagnostic solutions. Partnerships between public health agencies and private firms are also enhancing the availability of diagnostic tests in rural areas.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually emerging in the Hepatitis E diagnostic test market, holding approximately 5% of the global market share. The growth is primarily driven by increasing awareness of Hepatitis E and the need for improved diagnostic capabilities. However, challenges such as limited healthcare infrastructure and access to diagnostic tests hinder market expansion. Government initiatives aimed at enhancing healthcare access are crucial for future growth. Countries like South Africa and Nigeria are at the forefront of this market, with local players and international companies working to improve diagnostic solutions. The competitive landscape is characterized by collaborations between governments and NGOs to enhance public health initiatives. The presence of key players is growing, but significant investment is needed to overcome existing barriers.

## Competitive Benchmarking

The Hepatitis E Diagnostic Test Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of hepatitis E and the need for accurate diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, leveraging their extensive research capabilities and technological advancements to enhance their product offerings. Abbott Laboratories (US) focuses on innovation, particularly in developing rapid diagnostic tests that can be deployed in resource-limited settings, while Roche Diagnostics (CH) emphasizes partnerships with healthcare providers to expand its market reach. Siemens Healthineers (DE) is investing in digital transformation, integrating AI into its diagnostic platforms to improve accuracy and efficiency, thereby shaping a competitive environment that prioritizes technological advancement and strategic collaborations.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain resilience. The market appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies is significant. This competitive structure allows for a diverse range of diagnostic solutions, catering to various regional needs and regulatory requirements, which in turn fosters innovation and responsiveness to market demands.

In August  Abbott Laboratories (US) announced the launch of a new point-of-care hepatitis E test designed for use in low-resource environments. This strategic move is likely to enhance access to diagnostics in underserved regions, aligning with global health initiatives aimed at controlling hepatitis E outbreaks. The introduction of this test not only strengthens Abbott's product portfolio but also positions the company as a leader in addressing public health challenges.

In September  Roche Diagnostics (CH) expanded its collaboration with local health authorities in Southeast Asia to improve hepatitis E surveillance and testing capabilities. This partnership is strategically important as it allows Roche to leverage local expertise and infrastructure, thereby enhancing its market presence while contributing to regional health improvements. Such collaborations may also facilitate the development of tailored diagnostic solutions that meet specific local needs.

In July  Siemens Healthineers (DE) unveiled a new AI-driven diagnostic platform that integrates hepatitis E testing with other infectious disease diagnostics. This innovation is indicative of a broader trend towards integrated diagnostic solutions, which could streamline testing processes and improve patient outcomes. By adopting [AI](https://www.marketresearchfuture.com/reports/artificial-intelligence-market-1139)technologies, Siemens is likely to enhance its competitive edge, appealing to healthcare providers seeking efficient and comprehensive diagnostic tools.

As of October  the Hepatitis E Diagnostic Test Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and enhancing product offerings. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and respond to evolving healthcare needs.

## Recent News & Developments

- **Q1 2024: Roche launches new Elecsys HEV IgM and IgG immunoassays for hepatitis E virus diagnosis** Roche announced the launch of its Elecsys HEV IgM and IgG immunoassays, expanding its diagnostic portfolio to include tests for hepatitis E virus, aimed at improving early detection and disease management.
- **Q2 2024: Altona Diagnostics releases RealStar HEV RT-PCR Kit 3.0 for hepatitis E virus detection** Altona Diagnostics introduced the RealStar HEV RT-PCR Kit 3.0, a CE-IVD marked molecular diagnostic test for the detection of hepatitis E virus RNA, targeting clinical laboratories in Europe.
- **Q2 2024: Dia.Pro launches new HEV ELISA kits for improved hepatitis E diagnosis** Dia.Pro Diagnostic Bioprobes announced the launch of new ELISA kits for hepatitis E virus, designed to enhance sensitivity and specificity in clinical diagnostics.
- **Q2 2024: Wantai receives regulatory approval for HEV IgM rapid test in Southeast Asia** Beijing Wantai Biological Pharmacy Enterprise obtained regulatory clearance for its HEV IgM rapid diagnostic test in several Southeast Asian countries, expanding access to point-of-care hepatitis E testing.
- **Q3 2024: Fortress Diagnostics launches new hepatitis E rapid test for global markets** Fortress Diagnostics announced the global launch of its hepatitis E rapid test, designed for use in resource-limited settings to facilitate timely diagnosis.
- **Q3 2024: MP Biomedicals expands hepatitis E diagnostic portfolio with new molecular assay** MP Biomedicals introduced a new molecular assay for hepatitis E virus detection, aiming to improve diagnostic accuracy in clinical laboratories.
- **Q4 2024: Primerdesign launches CE-marked hepatitis E virus RT-PCR kit** Primerdesign announced the launch of a CE-marked RT-PCR kit for hepatitis E virus, targeting European clinical diagnostic markets.
- **Q4 2024: Gold Standard Diagnostics introduces new hepatitis E ELISA test for clinical use** Gold Standard Diagnostics released a new ELISA test for hepatitis E virus, designed to support laboratories in accurate serological diagnosis.
- **Q1 2025: Mikrogen launches recomLine HEV IgG/IgM immunoblot for hepatitis E confirmation** Mikrogen GmbH announced the launch of its recomLine HEV IgG/IgM immunoblot, a confirmatory test for hepatitis E virus serology.
- **Q2 2025: AccuBioTech receives CE-IVD approval for new hepatitis E rapid test** AccuBioTech Co., Ltd. received CE-IVD approval for its hepatitis E rapid test, enabling distribution across European markets.
- **Q2 2025: Dia.Pro partners with European distributor for hepatitis E diagnostic kits** Dia.Pro Diagnostic Bioprobes announced a partnership with a major European distributor to expand the reach of its hepatitis E diagnostic kits.
- **Q3 2025: Altona Diagnostics signs supply agreement for RealStar HEV RT-PCR kits with national health authority** Altona Diagnostics entered into a supply agreement with a national health authority to provide RealStar HEV RT-PCR kits for hepatitis E virus surveillance and outbreak response.

## Report Scope

| MARKET SIZE 2024 | 2.046(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.18(USD Billion) |
| MARKET SIZE 2035 | 4.12(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.57% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US), Siemens Healthineers (DE), Mylab Discovery Solutions (IN), Genetic Technologies Limited (AU), Wondfo Biotech (CN) |
| Segments Covered | Test Type, Sample Type, End Users, Regional |
| Key Market Opportunities | Advancements in rapid testing technologies enhance accessibility in the Hepatitis E Diagnostic Test Market. |
| Key Market Dynamics | Rising demand for rapid diagnostic tests drives innovation and competition in the Hepatitis E diagnostic test market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Hepatitis E Diagnostic Test Market by 2035?**
A: The Hepatitis E Diagnostic Test Market is projected to reach a valuation of 4.12 USD Billion by 2035.

**Q: What was the market valuation of the Hepatitis E Diagnostic Test Market in 2024?**
A: In 2024, the market valuation of the Hepatitis E Diagnostic Test Market was 2.046 USD Billion.

**Q: What is the expected CAGR for the Hepatitis E Diagnostic Test Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Hepatitis E Diagnostic Test Market during the forecast period 2025 - 2035 is 6.57%.

**Q: Which companies are considered key players in the Hepatitis E Diagnostic Test Market?**
A: Key players in the Hepatitis E Diagnostic Test Market include Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, and Siemens Healthineers.

**Q: What are the main test types in the Hepatitis E Diagnostic Test Market and their projected valuations?**
A: The main test types include Immunoassay-Based Tests, projected to reach 1.6 USD Billion, and Molecular Diagnostics Tests, expected to reach 1.2 USD Billion by 2035.

**Q: How does the market for serological tests in the Hepatitis E Diagnostic Test Market compare to other test types?**
A: Serological Tests are projected to reach 1.32 USD Billion by 2035, indicating a competitive position among test types.

**Q: What sample types are utilized in the Hepatitis E Diagnostic Test Market?**
A: The sample types include Serum, Plasma, and Fecal, with Serum expected to reach 1.6 USD Billion by 2035.

**Q: Which end users are driving the Hepatitis E Diagnostic Test Market?**
A: End users include Hospitals, Diagnostic Laboratories, and Research Institutes, with Hospitals projected to reach 1.64 USD Billion by 2035.

**Q: What is the projected growth trend for the Hepatitis E Diagnostic Test Market?**
A: The Hepatitis E Diagnostic Test Market is expected to experience steady growth, with a projected valuation increase from 2.046 USD Billion in 2024 to 4.12 USD Billion by 2035.

**Q: How do the projected revenues for diagnostic laboratories compare to hospitals in the Hepatitis E Diagnostic Test Market?**
A: Diagnostic Laboratories are projected to reach 1.25 USD Billion by 2035, while Hospitals are expected to achieve a higher valuation of 1.64 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hepatitis-e-diagnostic-test-market-29424*